CETP inhibitor evacetrapib enters mouse brain tissue.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• High plasma cholesterol, particularly LDL-C, is linked to increased Alzheimer's disease risk.
• Cholesteryl ester transfer protein (CETP) activity elevates LDL-C; reduced CETP activity correlates with cognitive benefits and lower Alzheimer's risk.
• CETP inhibitors are effective at lowering CETP activity and LDL-C, suggesting potential therapeutic use for Alzheimer's disease.

Purpose of the Study:

• To investigate the pharmacokinetic parameters of the CETP inhibitor evacetrapib in plasma, liver, and brain tissues.
• To determine if evacetrapib can cross the blood-brain barrier.
• To assess the potential of evacetrapib as a therapeutic agent for Alzheimer's disease.

Main Methods:

• Pharmacokinetic analysis of evacetrapib in CETP transgenic mice.
• Measurement of evacetrapib concentrations in plasma, liver, and brain tissues.
• Intravenous administration of evacetrapib at a 40 mg/kg dose.

Main Results:

• Evacetrapib was detected in brain tissue 0.5 hours after intravenous injection.
• Evacetrapib crosses the blood-brain barrier in a non-linear fashion.
• Pharmacokinetic parameters in plasma, liver, and brain were characterized.

Conclusions:

• Evacetrapib successfully crosses the blood-brain barrier.
• Evacetrapib shows potential as a candidate drug for treating Alzheimer's disease by addressing CETP-mediated cholesterol dysregulation.
• Further research is warranted to explore evacetrapib's efficacy in Alzheimer's disease models.